You are here:

MS in the Media - 14 September 2018

Published on

8 - 14 September 2018

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts

Ocrevus turned down for PPMS in England

NICE has not approved Ocrevus (ocrelizumab) for primary progressive MS, finding the drug not cost effective for use by the NHS in England.

Source: Daily Telegraph
Source: Independent
Source: Pharmafield

MS Trust link: NICE does not recommend ocrelizumab for primary progressive MS in England and Wales - news item

Ocrevus slows progression

A larger proportion of people taking Ocrevus showed no evidence of progression over two years compared to people taking a placebo according to a reanalysis of data from the Ocrevus (ocrelizumab) in primary progressive MS trial. Overall, most people did show signs of progression in both treatment and placebo groups

Source: MS News Today

MS Trust link: Ocrevus (ocrelizumab)

Prevalence of benign MS

Benign MS occurred in just 3% of people in a recent UK study. The defined benign MS as EDSS of three or lower, no significant fatigue, mood or cognitive symptoms, not on a disease modifying drug, and employment unaffected. The number of people in the study who defined themselves as having benign MS was much higher than those meeting the medical criteria

Source: MS News Today

MS Trust link: Types of MS

Statins trial starts in SPMS

A trial of simvastatin in SPMS had started recruiting.  MS-STAT2 will involve 1,180 people at 30 sites around the UK. People will be treated for three years, whole trial is expected to last five years

Source: UCLH

MS Trust link: Simvastatin

Gilenya effective in childhood MS

The previously announced results showing Gilenya (fingolimod) is an effective treatment in people with MS aged under 18 have been published in a medical journal.

Source: National MS Society (USA)

MS Trust link: Childhood MS

Print this page